4-benzyloxycarbonylamino-2-tert-butoxycarbonylamino-butyric acid | 47461-65-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-benzyloxycarbonylamino-2-tert-butoxycarbonylamino-butyric acid
• 英文别名: 4-(((benzyloxy)carbonyl)amino)-2-((tert-butoxycarbonyl)amino)butanoic acid；Boc-Gly(CH2CH2NH-Z)；4-Benzyloxycarbonylamino-2R-tert-butoxycarbonylamino-butyric acid；4-benzyloxycarbonylamino-2(S)-(-)-tert-butoxycarbonylaminobutyric acid；2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-(phenylmethoxycarbonylamino)butanoic acid
• CAS: 47461-65-4
• 化学式: C₁₇H₂₄N₂O₆
• 分子量: 352.387
• InChiKey: IILDIIAZNITTLB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  25
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-benzyloxycarbonylamino-2-tert-butoxycarbonylamino-butyric acid 在 N-甲基吗啉 、 sodium tetrahydroborate 、 草酰氯 、 四甲基乙二胺 、 2-氯-1-甲基吡啶碘化物 、 二甲基亚砜 、 三乙胺 、 三氟乙酸 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 69.88h， 生成 trans-4-[(4-methoxybenzyloxy)acetyl]-5-oxo-hexahydropyrrolo[3,2-b]pyrrole-1-carboxylic acid benzyl ester
  参考文献：
  名称：

  Design and Synthesis of Pyrrolidine-5,5-trans-lactams (5-Oxo-hexahydro-pyrrolo[3,2-b]pyrroles) as Novel Mechanism-Based Inhibitors of Human Cytomegalovirus Protease. 1. The α-Methyl-trans-lactam Template

  摘要：

  Mechanism-based inhibitors of human cytomegalovirus (HCMV) protease have been designed based on the pyrrolidine-5,5-trans-lactam ring system. New routes to the beta -methyl-, desmethyl-, and alpha -methyl-pyrrolidine-5,5-trans-lactam templates have been developed from 2,4-diaminobutyric acid. ESI/MS studies have shown that these inhibitors can bind covalently and reversibly to the viral enzyme in a time-dependent manner by a mechanism which is consistent; with acylation of HCMV delta Ala protease at the active site nucleophile Ser 132. SAR in this series of pyrrolidine-5,5-trans-lactams has defined the relative stereochemisty of the methyl substituent adjacent to the lactam carbonyl, the functionality on the lactam nitrogen, and the mechanism of action of this novel series of serine protease inhibitors against the HCMV dAla protease. Activity decreases on moving from the alpha -methyl to the desmethyl to the beta -methyl series. This selectivity is the opposite of that observed for these templates against the elastase and thrombin enzymes. The activity against HCMV delta Ala protease is the greatest with inhibitors based on the Cbz-protected alpha -methyl-5,5-trans-lactam template which have low micromolar activity against the viral enzyme.

  DOI：

  10.1021/jm000078q
• 作为产物：
  描述：

  氯甲酸苄酯 在 sodium hydroxide 、 copper diacetate 作用下， 以 1,4-二氧六环 为溶剂， 反应 25.5h， 生成 4-benzyloxycarbonylamino-2-tert-butoxycarbonylamino-butyric acid
  参考文献：
  名称：

  Design and Synthesis of Pyrrolidine-5,5-trans-lactams (5-Oxo-hexahydro-pyrrolo[3,2-b]pyrroles) as Novel Mechanism-Based Inhibitors of Human Cytomegalovirus Protease. 1. The α-Methyl-trans-lactam Template

  摘要：

  Mechanism-based inhibitors of human cytomegalovirus (HCMV) protease have been designed based on the pyrrolidine-5,5-trans-lactam ring system. New routes to the beta -methyl-, desmethyl-, and alpha -methyl-pyrrolidine-5,5-trans-lactam templates have been developed from 2,4-diaminobutyric acid. ESI/MS studies have shown that these inhibitors can bind covalently and reversibly to the viral enzyme in a time-dependent manner by a mechanism which is consistent; with acylation of HCMV delta Ala protease at the active site nucleophile Ser 132. SAR in this series of pyrrolidine-5,5-trans-lactams has defined the relative stereochemisty of the methyl substituent adjacent to the lactam carbonyl, the functionality on the lactam nitrogen, and the mechanism of action of this novel series of serine protease inhibitors against the HCMV dAla protease. Activity decreases on moving from the alpha -methyl to the desmethyl to the beta -methyl series. This selectivity is the opposite of that observed for these templates against the elastase and thrombin enzymes. The activity against HCMV delta Ala protease is the greatest with inhibitors based on the Cbz-protected alpha -methyl-5,5-trans-lactam template which have low micromolar activity against the viral enzyme.

  DOI：

  10.1021/jm000078q

文献信息

• Quinazoline derivatives useful in cancer treatment
  申请人：Mallams K. Alan

  公开号：US20070015774A1

  公开（公告）日：2007-01-18

  The present invention provides compounds of Formula I (wherein R 1 , R 2 , R 3 , L, and X are as defined herein). or a pharmaceutically acceptable salt, solvate or ester thereof. The present invention also provides compositions comprising these compounds that are useful for treating cellular proliferative diseases, disorders associated with activity of mutants of p53, or in causing apoptosis of cancer cells.

  本发明提供了式I的化合物（其中R1、R2、R3、L和X如本文所定义）。或其药用可接受的盐、溶剂或酯。本发明还提供了包含这些化合物的组合物，用于治疗细胞增殖性疾病、与p53突变体活性有关的疾病，或导致癌细胞凋亡。
• 4-Hydroxy-1,2,3-triazole moiety as bioisostere of the carboxylic acid function: a novel scaffold to probe the orthosteric γ-aminobutyric acid receptor binding site
  作者：Alessandro Giraudo、Jacob Krall、Birgitte Nielsen、Troels E. Sørensen、Kenneth T. Kongstad、Barbara Rolando、Donatella Boschi、Bente Frølund、Marco L. Lolli

  DOI：10.1016/j.ejmech.2018.08.094

  日期：2018.10

  specific target requirements. Among carboxylic acid isosters, as the hydroxylated pentatomic heterocyclic systems, the hydroxy-1,2,3-triazole represents one of the most versatile but less investigated. With the purpose to enlarge its bioisosteric application, we report the results of a study devoted to obtain potential biomimetics of the γ-aminobutyric acid (GABA), the major inhibitory neurotransmitter

  生物（等）位取代的正确应用（设计优化化合物的有效工具）需要不断开发能够响应特定目标要求的新等位基因。在羧酸的等排体中，作为羟基化的五原子杂环系统，羟基-1,2,3-三唑是用途最广但研究较少的一种。为了扩大其生物甾体的应用，我们报告了一项研究结果，该研究致力于获得γ-氨基丁酸（GABA）（中枢神经系统（CNS）中的主要抑制神经递质）的潜在仿生体。一系列的N 1-和N 2-已经合成并在药理学上表征了先前报道的GABA A R配体的功能化的4-羟基-1,2,3-三唑类似物，包括muscimol，4-PIOL和4-PHP。此外，这项研究还导致了直接化学方法的发展，该策略旨在装饰羟基三唑核心支架，为基于该系统的进一步详细研究打开了方便之门。未取代的N 1-和N 2-哌啶-4-基-4-羟基-1,2,3-三唑类似物（3a，4a）的4-PIOL和4-PHP表现出较弱的亲和力（高至中微摩尔范围），而用2-萘甲基或3
• New alpha-amino acid sulphonyl compounds
  申请人：——

  公开号：US20030087950A1

  公开（公告）日：2003-05-08

  Compound of formula (I): 1 wherein: 2 represents an optionally substituted, 5-membered, nitrogen-containing heterocycle, R 1 represents hydrogen, alkyl, acyl, prolyl, alanyl, histidylprolyl or phenylalanylprolyl, Ak represents an alkylene or heteroalkylene chain, X represents a single bond or optionally substituted phenylene, R 2 represents optionally substituted alkyl, (C 3 -C 10 )cycloalkyl, or —NR 2a R 2b wherein R 2a and R 2b , which may be the same or different, each represent hydrogen or alkyl or, together with the nitrogen atom carrying them, form a nitrogen-containing heterocycle, 3 R 3 represents hydrogen or a group selected from alkyl, (C 3 -C 7 ) cycloalkyl and aryl, R 4 , R 5 and R 6 , which may be the same or different, each represent hydrogen or alkyl, or R 4 and R 6 , or R 5 and R 6 , together with the atoms carrying them, form an imidazolidine or dihydrobenzimidazole ring, its optical isomers and addition salts thereof with a pharmaceutically acceptable acid, and medicinal products containing the same which are useful as inhibitors of dipeptidyl-peptidase IV.

  式(I)的化合物：其中：2代表一个可选择取代的5-元素含氮杂环，R1代表氢、烷基、酰基、脯氨酰基、丙氨酰基、组氨酰脯氨酰基或苯基丙氨酰基，Ak代表一个烷基或杂原子烷基链，X代表一个单键或可选择取代的苯基，R2代表可选择取代的烷基、(C3-C10)环烷基，或-NR2aR2b，其中R2a和R2b，可以相同也可以不同，每个代表氢或烷基，或者与携带它们的氮原子一起形成含氮杂环，R3代表氢或从烷基、(C3-C7)环烷基和芳基中选择的一个基团，R4、R5和R6，可以相同也可以不同，每个代表氢或烷基，或R4和R6，或R5和R6，与携带它们的原子一起形成咪唑烷或二氢苯并咪唑环，其光学异构体及其与药学上可接受的酸的加合盐，以及含有这种化合物的药物产品，用作二肽基肽酶IV的抑制剂。
• Potent Dmt-Tic Pharmacophoric δ- and μ-Opioid Receptor Antagonists
  作者：Tingyou Li、Yoshio Fujita、Kimitaka Shiotani、Anna Miyazaki、Yuko Tsuda、Akihiro Ambo、Yusuke Sasaki、Yunden Jinsmaa、Ewa Marczak、Sharon D. Bryant、Severo Salvadori、Lawrence H. Lazarus、Yoshio Okada

  DOI：10.1021/jm050377l

  日期：2005.12.1

  A series of dimeric Dmt-Tic (2',6'-dimethyl-L-tyrosyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) analogues (8-14, 18-22) were covalently linked through diaminoalkane and symmetric or asymmetric 3,6-diaminoalkyl-2(1H)-pyrazinone moieties. All the compounds exhibited high affinity for both 6-opioid receptors K(6) = 0.06-1.53 nM] andy-opioid receptors [K-i(mu) = 1.375.72 nM], resulting in moderate delta-receptor selectivity [K-i(mu)/K-i(delta) = 3-46]. Regardless of the type of linker between the Dmt-Tic pharmacophores, delta-opioid-mediated antagonism was extraordinarily high in all analogues (pA(2) = 10.42-11.28), while in vitro agonism (MVD and GPI bioassays) was essentially absent (ca. 3 to > 10 mu M). While an unmodified N-terminus (9, 13, 18) revealed weaku-opioid antagonism (pA(2) = 6.78-6.99), N,N'-dimethylation (21, 22), which negatively impacts on mu-opioid-associated agonism (Balboni et al., Bioorg. Med. Chem. 2003, 11, 5435-5441), markedly enhanced mu-opioid antagonism (pA(2) = 8.34 and 7.71 for 21 and 22, respectively) without affecting 6-opioid activity. These data are the first evidence that a single dimeric opioid ligand containing the Dmt-Tic pharmacophore exhibits highly potent 6- andy-opioid antagonist activities.
• PYRROLOPYRROLONE DERIVATIVES AS INHIBITORS OF NEUTROPHIL ELASTASE
  申请人：GLAXO GROUP LIMITED

  公开号：EP0891362B1

  公开（公告）日：2004-03-17